Disclaimer

The office of the British Association for Psychopharmacology (BAP) receives many queries from members of the general public, from health professionals and journalists on matters related to pre-clinical and clinical psychopharmacology. Some of these queries may be passed on to the membership, for example when they are raised by researchers and health professionals and relate to general aspects of behavioural or clinical psychopharmacology: the opinions given will be those of the individual member, and cannot be regarded as the opinion of the BAP. Queries relating to individual cases (such as concerns regarding patient management) cannot be addressed by the BAP. Patients who are concerned about their treatment are advised to discuss their worries with their general practitioner, or with others who may be involved in their care. Discussions with BAP Members are necessarily limited by accepted standards of confidentiality, ethics and professional practice.